natgillin/translations-raw huggingface dataset:
Metabolism and nutrition disorders common hypertriglyceridaemia, hyperlipidaemia uncommon anorexia, decreased appetite, weight decreased, hyperamylasaemia, hypercholesterolaemia, diabetes mellitus, hyperglycaemia rare dehydration
Poremećaji metabolizma i prehrane često hipertrigliceridemija, hiperlipidemija manje često anoreksija, smanjeni apetit, smanjena tjelesna težina, hiperamilazemija, hiperkolesterolemija, dijabetes melitus, hiperglikemija rijetko dehidracija
In addition, co-administration of Aptivus with low dose ritonavir, and medicinal products that are highly dependent on CYP2D6 for clearance, such as the antiarrhythmics flecainide, propafenone and metoprolol given in heart failure (see section 4.5).
Nadalje, istodobna primjena Aptivusa i niske doze ritonavira s lijekovima čiji klirens izrazito ovisi o CYP2D6, kao što su antiaritmici flekainid, propafenon i metoprolol, koji se daju u zatajenju srca (vidjeti dio 4.5).
Aptivus/ritonavir should not be administered concomitantly with cobicistat or cobicistat-containing products.
Aptivus/ritonavir se ne smiju primjenjivati istodobno s kobicistatom ili lijekovima koji sadrže kobicistat.
The superiority of tipranavir co-administered with low dose ritonavir over the comparator protease inhibitor/ritonavir arm was observed for all efficacy parameters at week 48.
Superiornost tipranavira s niskom dozom ritonavira, u odnosu na kontrolnu skupinu, inhibitor proteaze/ritonavir, uočena je za sve pokazatelje djelotvornosti nakon 48 tjedana.
Concomitant use of Aptivus, co-administered with low dose ritonavir, with the protease inhibitors amprenavir, lopinavir or saquinavir (each co-administered with low dose ritonavir) in a dual-boosted regimen, results in significant decreases in plasma concentrations of these protease inhibitors.
Istodobna primjena Aptivusa s niskom dozom ritonavira, i inhibitora proteaze amprenavira, lopinavira ili sakvinavira (svaki se primjenjuje s niskom dozom ritonavira) u dvostrukom pojačanom režimu, rezultira značajnim smanjenjima koncentracija u plazmi ovih inhibitora proteaze.
Compared to the capsules, tipranavir exposure is higher when administering the same dose as oral solution (see section 5.2).
U usporedbi s kapsulama izlaganje tipranaviru je veće nakon primjene oralne otopine (vidjeti dio 5.2).
In HIV-infected patients with severe immune deficiency at the time of initiation of combination antiretroviral therapy (CART), an inflammatory reaction to asymptomatic or residual opportunistic infections may arise.
U HIV-om zaraženih bolesnika s teškom imunodeficijencijom, u trenutku početka kombinirane antiretrovirusne terapije, može doći do upalne reakcije na asimptomatske ili rezidualne oportunističke infekcije.
Key efficacy results at 48 weeks for patients 2 - <12 years treated with Aptivus oral solution Endpoint
Ključni rezultati učinkovitosti na kraju 48 tjedana liječenja za bolesnike 2 - < 12 godina starosti liječene Aptivus oralnom otopinom
Clear yellow viscous liquid.
Bistra viskozna tekućina žute boje.
- Sleepiness - Dizziness - Numbness and/or tingling and/or pain in the feet or hands - Breathing difficulties - Heartburn - Inflammation of the pancreas - Skin inflammation - Itching - Muscle cramp - Muscle pain - Kidney disease - Flu like symptoms (feeling unwell) - Fever - Weight loss - Increased blood levels of the pancreas enzyme amylase - Increases in liver enzyme activity - Hepatitis with liver cell damage due to influence of a toxin
- pospanost - omaglica - odumrlost i/ili trnci i/ili bol u stopalima ili rukama - poteškoće s disanjem - žgaravica - upala gušterače - upala kože - svrbež - grč mišića - bol u mišićima - bolest bubrega - simptomi slični gripi (osjećaj lošeg stanja) - vrućica - gubitak težine - povišene vrijednosti amilaze, enzima gušterače, u krvi - povećana aktivnost jetrenog enzima - hepatitis s oštećenjem jetrene stanice zbog utjecaja toksina
Hepatobiliary disorders uncommon hepatic enzyme increased (ALAT, ASAT), cytolytic hepatitis, liver function test abnormal (ALAT, ASAT), hepatitis toxic rare hepatic failure (including fatal outcome), hepatitis, hepatic steatosis, hyperbilirubinaemia
Poremećaji jetre i žuči manje često povišeni jetreni enzimi (ALT, AST), citolitički hepatitis, abnormalni nalaz testa jetrene funkcije (ALT, AST), toksični hepatitis rijetko zatajenje jetre (uključujući fatalni ishod), hepatitis, hepatička steatoza, hiperbilirubinemija
Combined 48-week treatment response (composite endpoint defined as patients with a confirmed 1 log RNA drop from baseline and without evidence of treatment failure) for both studies was 34% in the tipranavir with ritonavir arm and 15% in the comparator arm.
Kombinirani 48-tjedni rezultati za dvije studije (kompozitni ishod: bolesnici s potvrđenim 1 log RNA padom u odnosu na početne vrijednosti i bez dokaza o neuspjehu liječenja) pokazali su da je kompozitni ishod postignut u 34% bolesnika na tipranaviru s ritonavirom te u 15% bolesnika u kontrolnoj skupini.
What Aptivus contains - The active substance is tipranavir.
Što Aptivus sadrži - Djelatna tvar je tipranavir.
low dose ritonavir (this helps Aptivus to reach a high enough level in your child's blood) other HIV medicines.
niskom dozom ritonavira (koji pomaže Aptivusu u postizanju dovoljno visokih vrijednosti u djetetovoj krvi) drugim HIV lijekovima.
In studies where tipranavir coadministered with low-dose ritonavir was used with or without enfuvirtide, it has been observed that the steady-state plasma tipranavir trough concentration of patients receiving enfuvirtide were 45% higher as compared to patients not receiving enfuvirtide.
U ispitivanjima u kojima je tipranavir s niskom dozom ritonavira rabljen sa ili bez enfuvirtida, primijećeno je da su koncentracije tipranavira na kraju dozirnog intervala u stanju dinamičke ravnoteže bile 45% više u bolesnika koji su primali enfuvirtid.
Aptivus, co-administered with low dose ritonavir, should be used with caution in patients who may be at risk of increased bleeding from trauma, surgery or other medical conditions, or who are receiving medicinal products known to increase the risk of bleeding such as antiplatelet agents and anticoagulants or who are taking supplemental vitamin E. Patients taking Aptivus oral solution should be advised not to take any supplemental vitamin E.
Aptivus s niskom dozom ritonavira treba se primjenjivati s oprezom u bolesnika u kojih postoji rizik pojačanog krvarenja zbog traume, kirurškog zahvata ili drugih medicinskih stanja, ili koji dobivaju lijekove za koje se zna da povećavaju rizik krvarenja, kao što su antitrombotici i antikoagulansi, ili koji uzimaju dodatak vitamina E.
Hence tipranavir at therapeutic dose with low dose of ritonavir did not prolong the QTc interval but may do so at supratherapeutic dose.
Stoga, tipranavir terapijskoj dozi, s niskom dozom ritonavira, nije produljio QTc interval, već to može učiniti u supraterapijskoj dozi.
Therefore, patients should be monitored for opiate withdrawal syndrome.
Stoga je potrebno pratiti bolesnike radi sindroma opijatne apstinencije.
You must not breast-feed your baby because it is possible that the baby can become HIV-infected through the breast milk.
Ne smijete dojiti dijete jer postoji mogućnost prijenosa HIV-a putem majčinog mlijeka.
The following clinical safety features (hepatotoxicity, hyperlipidaemia, bleeding events, rash) were seen at higher frequency among tipranavir with ritonavir treated patients when compared with the comparator arm treated patients in the RESIST trials, or have been observed with tipranavir with ritonavir administration.
Sljedeća obilježja kliničke sigurnosti (hepatotoksičnost, hiperlipidemija, epizode krvarenja, osip) su primijećena s većom učestalošću među bolesnicima liječenim tipranavirom s ritonavirom u usporedbi s bolesnicima u kontrolnoj skupini u ispitivanjima RESIST, ili su primijećena u primjeni tipranavira s ritonavirom.
Aptivus contains macrogolglycerol ricinoleate which may cause stomach upset and diarrhoea.
Aptivus sadrži makrogolglicerol ricinoleat koji može uzrokovati želučane tegobe i proljev.
(N=740) versus +4 cells/mm
3 za ispitivanu skupinu (N=740) i +4 stanice/mm
In the case of concomitant antiviral therapy for hepatitis B or C, please refer also to the relevant Summary of Product Characteristics for these medicinal products.
U slučaju istodobnog antivirusnog liječenja hepatitisa B ili C, valja konzultirati Sažetak opisa svojstava lijeka za svaki korišteni lijek za hepatitis.
In addition the majority of participants had mutations associated with both NRTI and NNRTI resistance.
Nadalje, većina bolesnika imala je viruse s mutacijama povezanim s otpornošću i na NRTI i NNRTI.
In use storage: 60 days (below 25°C), after first opening of the bottle.
Čuvanje tijekom primjene: 60 dana (ispod 25°C), nakon prvog otvaranja boce.
Aptivus oral solution should be taken with food.
Aptivus oralna otopina se mora uzeti s hranom.
Herbal preparations containing St John's wort (Hypericum perforatum) due to the risk of decreased plasma concentrations and reduced clinical effects of tipranavir (see section 4.5).
Biljni pripravci koji sadrže gospinu travu (Hypericum perforatum) zbog rizika od smanjenih koncentracija u plazmi i smanjenih kliničkih učinaka tipranavira (vidjeti dio 4.5).
Anti-infectives
Antiinfektivni lijekovi
Since tipranavir is highly protein bound, dialysis is unlikely to be beneficial in significant removal of this medicine.
S obzirom da se tipranavir uvelike veže na proteine plazme, dijaliza vjerojatno neće pospješiti uklanjanje tipranavira.
First-dose tipranavir/r Digoxin Cmax ↔ Digoxin AUC ↔
Prva doza tipranavira/r Digoksin Cmax ↔ Digoksin AUC ↔
A reduced virological response was observed in patients with viral strains harbouring two or more mutations at HIV protease codons 33, 82, 84 or 90, and not receiving new enfuvirtide.
Smanjena virološka reakcija primijećena je u bolesnika s virusnim sojevima s dvije ili više mutacija u HIV proteaznim kodonima 33, 82, 84 ili 90, koji ne primaju „novi“ enfuvirtid.
These active substances include antiarrhythmics (such as amiodarone, bepridil, quinidine), antihistamines (such as astemizole, terfenadine), ergot derivatives (such as dihydroergotamine, ergonovine, ergotamine, methylergonovine), gastrointestinal motility agents (such as cisapride), antipsychotics (such as pimozide, sertindole, quetiapine, lurasidone), sedatives/hypnotics (such as orally administered midazolam and triazolam) and HMG-CoA reductase inhibitors (such as simvastatin and lovastatin) (see section 4.5).
Ove djelatne tvari uključuju antiaritmike (kao što su amiodaron, bepridil, kinidin), antihistaminike (kao što su astemizol, terfenadin), derivate ergota (kao što su dihidroergotamin, ergonovin, ergotamin, metilergonovin), lijekove za gastrointestinalnu pokretljivost (kao što je cisaprid), antipsihotike (kao što su pimozid, sertindol, kvetiapin, lurasidon), sedative/hipnotike (kao što su oralni midazolam i triazolam) te pri primjeni inhibitora HMG-CoA reduktaze (kao što su simvastatin i lovastatin) (vidjeti dio 4.5).
Patients were required to have a baseline HIV-1 RNA concentration of at least 1500 copies/ml, were stratified by age (2 to < 6 years, 6 to < 12 years and 12 to 18 years) and randomized to receive one of two tipranavir with ritonavir dose regimens: 375 mg/m2/150 mg/m dose, compared to the 290 mg/m2/115 mg/m2 dose, plus background therapy of at least two nonprotease inhibitor antiretroviral medicinal products, optimized using baseline genotypic resistance testing.
Morali su imati početnu vrijednost HIV-1 RNA najmanje 1500 kopija/ml, stratificirani su po dobi (od 2 do < 6 godina, od 6 do < 12 godina, te od 12 do 18 godina) i randomizirani na jedan od dvaju režima tipranavira s ritonavirom: doza od 375 mg/m2/150 mg/m2 ili 290 mg/m2/115 mg/m2, plus osnovna terapija s najmanje dva neproteazna antiretrovirusna lijeka, koji su bili optimizirani pomoću početnog testiranja genotipske rezistencije.
Co-administration of protease inhibitors with rifampicin substantially decreases protease inhibitor concentrations.
Istodobna primjena inhibitora proteaze s rifampicinom znatno smanjuje koncentracije inhibitora proteaze.
P-gp activity is significantly inhibited after the first dose, but there was a slight induction at steady state.
Aktivnost P-gpa je značajno inhibirana nakon prve doze, ali je u stanju dinamičke ravnoteže uočena blaga indukcija.
low dose ritonavir (this helps Aptivus to reach a high enough level in your blood) other HIV medicines.
niskom dozom ritonavira (koji pomaže Aptivusu u postizanju dovoljno visokih vrijednosti u krvi) drugim HIV lijekovima.
Your child's doctor will take a blood sample to test how well your child's liver is working (your child's liver function).
Djetetov liječnik će uputiti uzorke krvi Vašeg djeteta na testiranje koliko dobro funkcionira njegova jetra (jetrena funkcija).
If the coadministration is judged unavoidable, this should be done under close clinical monitoring.
Ako se istodobna primjena ocijeni nužnom, potrebno je pažljivo kliničko praćenje.
Additional side effects in children and adolescents The most common side effects were generally similar to those described in adults.
Najčešće nuspojave su općenito bile slične pojavama opisanima za odrasle osobe.
Dosing with Aptivus capsules 500 mg twice daily concomitant with 200 mg ritonavir twice daily for 2 to 4 weeks and without meal restriction produced a mean tipranavir peak plasma concentration (Cmax) of 94.8 ± 22.8 µM for female patients (n=14) and 77.6 ± 16.6 µM for male patients (n=106), occurring approximately 3 hours after administration.
Doziranje Aptivus kapsula 500 mg dvaput dnevno istodobno s 200 mg ritonavira, u trajanju 2 do 4 tjedana i bez ograničenja u obrocima hrane, rezultiralo je prosječnom vršnom koncentracijom tipranavira u plazmi (Cmax) od 94,8 ± 22,8 µM za ženske bolesnike (n=14) i 77,6 ± 16,6 µM za muške bolesnike (n=106), s Tmax oko 3 sata.
In rats, co-administration with vitamin E increased the bleeding effects of tipranavir (see section 5.3).
U štakora je istodobna primjena vitamina E povećala učinke tipranavira na krvarenje (vidjeti dio 5.3).
Tipranavir, co-administered with low dose ritonavir, is expected to decrease meperidine concentrations and increase normeperidine metabolite concentrations.
Očekuje se da tipranavir s niskom dozom ritonavira smanjuje koncentracije meperidina i povećava koncentracije metabolita normeperidina.
Aptivus co-administered with low dose ritonavir, has been associated with reports of significant liver toxicity.
Primjena Aptivusa s niskom dozom ritonavira povezuje se s prijavama značajne toksičnosti za jetru.
The safety and efficacy of Aptivus in children under 2 years of age has not been established.
Sigurnost i djelotvornost Aptivusa u djece u dobi ispod 2 godine nisu ustanovljene.
If you notice any symptoms of infection (for example fever, enlarged lymph nodes), please inform your doctor immediately.
Ako primijetite simptome infekcije (na primjer vrućica, povećani limfni čvorovi), odmah se obratite svom liječniku.
Interaction table
Tablica s interakcijama
Co-administration of Aptivus and low dose ritonavir with agents primarily metabolised by CYP3A may result in changed plasma concentrations of tipranavir or the other agents, which could alter their therapeutic and undesirable effects (see list and details of considered agents, below).
Istodobna primjena Aptivusa i niske doze ritonavira s lijekovima koji se prvenstveno metaboliziraju putem CYP3A može rezultirati promijenjenim koncentracijama tipranavira ili drugih lijekova u plazmi, što može promijeniti njihove terapijske i neželjene učinke (vidjeti popis relevantnih lijekova u nastavku).
3, respectively, (ranges 1-1893 and 1
3 (raspon 1-1893), a u kontrolnoj 166
If you miss a dose of Aptivus and/or ritonavir by less than 5 hours, take your missed dose immediately.
Ako propustite dozu Aptivusa i/ili ritonavira za manje od 5 sati, odmah uzmite propuštenu dozu.
If you have any further questions about ritonavir or the other medicines your child is prescribed, please ask your child's doctor or pharmacist.
Ako imate dodatnih pitanja o ritonaviru ili drugim lijekovima koji su propisani Vašem djetetu, obratite se djetetovom liječniku ili ljekarniku.
The in vivo net effect of tipranavir with ritonavir on CYP 1A2, CYP 2C9 and CYP 2C19, indicates, through a preliminary study, an inducing potential of tipranavir with ritonavir on CYP1A2 and, to a lesser extent, on CYP2C9 and P-gp after several days of treatment.
Preliminarno ispitivanje pokazuje da in vivo neto-učinak tipranavira s ritonavirom na CYP 1A2, CYP 2C9 i CYP 2C19 ukazuje na inducirajući potencijal tipranavira s ritonavirom na CYP1A2 te, u manjoj mjeri, na CYP2C9 i P-gp nakon nekoliko dana liječenja.
In use storage: 60 days (below 25°C) after first opening of the bottle.
Čuvanje tijekom primjene: 60 dana (ispod 25°C) nakon prvog otvaranja boce.
Most frequently reported moderate or severe adverse reactions in paediatric patients age 2 to < 12 years (reported in 2 or more children, Trial 1182.14, 48 weeks analyses, Full Analysis Set).
Najčešće umjerene ili teške nuspojave u pedijatrijskoj populaciji u dobi od 2 do <12 godina (prijavljeno za 2 ili više djece, Ispitivanje 1182.14, analize 48 tjedana, svi ispitanici).
R-methadone Cmax ↓ 46% R-methadone AUC ↓ 48%
R-metadon Cmax ↓ 46% R-metadon AUC ↓ 48%
Colchicine is a substrate of CYP3A4 and P-gp (an intestinal efflux transporter).
Kolhicin je supstrat CYP3A4 i P-gp (crijevni efluksni prijenosnik).
After 48 weeks of follow-up, the frequency of Grade 3 or 4 ALAT and/or ASAT abnormalities was higher in tipranavir with ritonavir patients compared with comparator arm patients (10% and 3.4%, respectively).
Nakon 48 tjedana praćenja, učestalost povišenja ALT i/ili AST 3. ili 4. stupnja bila je viša u bolesnika koji su dobivali kombinaciju tipranavira s ritonavirom u usporedbi s bolesnicima u kontrolnoj skupini (10% naspram 3,4%).
Didanosine Cmax ↓ 24% Didanosine AUC ↔
Didanozin Cmax ↓ 24% Didanozin AUC ↔
Uncommon: may affect up to 1 in 100 people - Reduction in red and white blood cells - Reduction in blood platelets - Allergic (hypersensitivity) reactions - Decreased appetite - Diabetes - Increased blood sugar - Increased blood levels of cholesterol - Sleeplessness and other sleep disorders
Manje često: mogu se javiti u do 1 na 100 osoba - smanjenje broja crvenih i bijelih krvnih stanica - smanjenje trombocita - alergijske reakcije (preosjetljivosti) - smanjeni apetit - dijabetes - povišeni šećer u krvi - povišene vrijednosti kolesterola u krvi - nesanica i drugi poremećaji spavanja
C-tipranavir to subjects (n = 8) that received 500 mg tipranavir with 200 mg ritonavir twice daily dosed to steady-state demonstrated that most radioactivity (median 82.3%) was excreted in faeces, while only a median of 4.4% of the radioactive dose administered was recovered in urine.
C-tipranavira ispitanicima (n = 8) koji su primali 500 mg tipranavira s 200 mg ritonavira dvaput dnevno, dozirano do stanja ravnoteže, pokazala je da se većina radioaktivnosti (prosjek 82,3%) izlučuje stolicom, dok je prosječno samo 4,4% primijenjene radioaktivne doze nađeno u urinu.
Oral contraceptives / Oestrogens Ethinyl oestradiol 0.035 mg / Norethindrone 1.0 mg QD (TPV/r 750/200 mg BID)
Oralni kontraceptivi / estrogeni Etinilestradiol 0,035 mg / Noretindron 1,0 mg QD (TPV/r 750/200 mg BID)
Aptivus is available as soft capsules for adults and adolescents from 12 years of age (please refer to the respective SmPC for further details).
Aptivus je dostupan u obliku mekih kapsula za odrasle osobe i adolescente od 12 godina starosti (vidjeti Sažetak opisa svojstava lijeka za Aptivus kapsule).
If the co-administration is nevertheless considered necessary, a close monitoring of the safety of tipranavir and a monitoring of plasma concentrations of atazanavir are strongly encouraged (see section
Ako se istodobna primjena ipak smatra potrebnom, valja pomno pratiti sigurnost tipranavira i koncentracije atazanavira u plazmi (vidjeti dio 4.4).
In deciding to initiate treatment with Aptivus, co-administered with low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents.
Prilikom odluke o početku liječenja Aptivusom uz istodobnu primjenu niske doze ritonavira, potrebno je pažljivo razmotriti povijest liječenja pojedinog bolesnika te obrasce mutacija povezanih s različitim lijekovima.
Since the renal clearance of tipranavir is negligible, increased plasma concentrations are not expected in patients with renal impairment.
S obzirom da je bubrežni klirens tipranavira neznatan, ne očekuju se povišene koncentracije u plazmi u bolesnika s oštećenjem bubrega.
- sildenafil, vardenafil, tadalafil (medicines used to produce and maintain an erection).
Oni mogu smanjiti učinkovitost Aptivusa. - sildenafil, vardenafil, tadalafil (lijekovi koji se primjenjuju za stvaranje i održavanje erekcije).
This is partly linked to restored health and life style, and in the case of blood lipids sometimes to the HIV medicines themselves.
Tijekom terapije HIV-a može doći do povećanja tjelesne težine i razine lipida i glukoze u krvi, što je djelomično povezano s obnovljenim zdravstvenim stanjem i stilom života, a u slučaju lipida u krvi ponekad i sa samim lijekovima za HIV.
Immunosupressants Cyclosporin Tacrolimus Sirolimus
Imunosupresivi Ciklosporin
Aptivus, co-administered with low dose ritonavir, when combined with warfarin may be associated with changes in INR (International Normalised Ratio) values, and may affect anticoagulation (thrombogenic effect) or increase the risk of bleeding.
Kad se Aptivus s niskom dozom ritonavira kombinira s varfarinom, može biti povezan s promjenama vrijednosti INR (international normalized ratio) te može smanjiti antikoagulantni učinak ili povećati rizik krvarenja.
Fatal and non-fatal intracranial haemorrhages (ICH) have been reported in patients receiving Aptivus, many of whom had other medical conditions or were receiving concomitant medicinal products that may have caused or contributed to these events.
Fatalna i nefatalna intrakranijalna krvarenja (intracranial hemorrhage, ICH) prijavljena su u bolesnika koji su dobivali Aptivus, od kojih su mnogi imali druga medicinska stanja ili su istodobno dobivali lijekove koji su mogli izazvati ili doprinijeti ovim događajima.
Steady-state tipranavir/r: Midazolam Cmax ↓ 13% Midazolam AUC ↑ 181%
Tipranavir/r u stanju ravnoteže: Midazolam Cmax ↓ 13% Midazolam AUC ↑ 181%
This will depend on, for example: which other medicines you have already taken for HIV which medicines your HIV is resistant to.
Liječnik će, u suradnji s Vama, odlučiti koje druge lijekove trebate uzimati, što će ovisiti, na primjer: o tome koje ste druge lijekove već uzimali protiv HIV-a o tome na koje lijekove je Vaš HIV otporan.
Each capsule contains 250 mg tipranavir.
Svaka kapsula sadrži 250 mg tipranavira.
Tipranavir is metabolised by the hepatic system.
Tipranavir se metabolizira putem jetrenih enzima.
Gastrointestinal disorders very common diarrhoea, nausea common vomiting, flatulence, abdominal pain, abdominal distension, dyspepsia uncommon gastrooesophageal reflux disease, pancreatitis rare lipase increased
Poremećaji probavnog sustava vrlo često proljev, mučnina često povraćanje, nadutost, bol u abdomenu, distenzija abdomena, dispepsija manje često gastroezofagealna refluksna bolest, pankreatitis rijetko povišena lipaza
In an open-label, dose-finding study of tipranavir plus ritonavir (Trial 1182.14), 28 children who were 12 years of age or above received Aptivus capsules.
U otvorenom ispitivanju određivanja doze tipranavira s ritonavirom (ispitivanje 1182.14), 28 djece u dobi 12-18 godina dobivalo je Aptivus kapsule.
Therefore, Aptivus should be used with caution, and with increased monitoring frequency, in patients with mild hepatic impairment (ChildPugh Class A).
Stoga se Aptivus primjenjuje s oprezom, i uz učestalije praćenje, u bolesnika s blagim oštećenjem jetre (Child-Pugh stadij A).
The interaction profile of tipranavir, co-administered with low dose ritonavir, is complex.
Profil interakcija tipranavira s niskom dozom ritonavira je složen.